Aether Pacific Pharmaceuticals, formerly Medical Kiwi. New Website Coming Soon.

Medical Kiwi

Statement to Interested Parties

18 March 2021

Medical Kiwi dedicated to medicinal cannabis industry growth

Medical Kiwi Limited is dedicated to the growth of a highly credible medicinal cannabis industry in New Zealand which the company believes will, in time, produce affordable medicines for Kiwi patients, foreign exchange earnings for the nation and good returns for investors 

Medical Kiwi Chairman Aldo Miccio says the company has so far raised capital from seed investors and crowdfunding shareholders who hold the same vision, secured all licencing required for its activities, and begun cultivation of a first crop at a state-of-the-art facility in Christchurch

“We are working through the standard approvals process for NZSX listing in the very near future,” Mr Miccio says.  “Direct listing without further capital raising at this stage is clearly a demonstration of our confidence, and a reflection of the rigour in our business planning and early-stage operations

He says Medical Kiwi looks forward to providing more information about its business and its outlook at the point of listing.  “Of course, we accept all the obligations which come with being a listed New Zealand company thereafter.

“We agree with the New Zealand Medical Cannabis Council that all parties in this industry need to accurately represent the opportunities and risks involved in producing, processing and supplying medicinal cannabis, and that doing this is not always easy,” Mr Miccio says.

“Ultimately Kiwi investors will decide which businesses are worthy of their support because they have the vision, resources, business plan and competencies to grow and prosper.  NZSX listing makes it easier for investors to decide!”

Mr Miccio says Medical Kiwi will continue to concentrate on meeting the expectations of customers, shareholders and regulators, without distraction from other parties who might criticise from the industry sidelines.


Medical Kiwi will make no further comment prior to proposed NZSX listing.